Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-BCMA + anti-GPRC5D CAR-T cells
- Development stage
- Unknown
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy, developed by the Shenzhen Geno-Immune Medical Institute (GIMI), is a dual-targeted chimeric antigen receptor (CAR) T-cell product designed for the treatment of high-risk multiple myeloma and plasmacytoma. The therapy utilizes GIMI's 4SCAR2.0 platform to simultaneously or sequentially target two key myeloma-associated antigens: B-cell maturation antigen (BCMA) and G protein-coupled receptor, class C, group 5, member D (GPRC5D). By targeting two distinct antigens, the therapy aims to overcome the challenge of antigen escape-mediated relapse, which is a common limitation of single-target CAR-T therapies. It is currently being evaluated in Phase 1/2 clinical trials as a frontline treatment approach to improve deep and durable responses in patients with high-risk disease profiles.
- Other names
- BCMA and GPRC5D Combination CAR-T Cell TherapyFrontline BCMA and GPRC5D CAR-TCAR-T cells-Shenzhen Geno-Immune Medical Institute-multiple myeloma-plasmacytoma
02
Targets
BCMA (B-cell maturation antigen)GPRC5D
Beyond the preview
Go deeper on anti-BCMA + anti-GPRC5D CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-BCMA + anti-GPRC5D CAR-T cells.